Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The drug-induced sarcoidosis-like reaction (DISR) is a condition clinically and pathologically similar to sarcoidosis but is induced by certain drugs. A few cases of DISR associated with the use of TNF-α antagonists have been reported in the literature.
Case Report: A 49-year-old female patient with a diagnosis of Crohn's Disease under treatment with adalimumab presented with a 2-month-long ulcerated swelling in the left lower fornix. Histological analysis of the biopsy specimen revealed multiple non-caseating granulomas multinucleated cells and epithelioid macrophages surrounded by lymphocytes. The lesion is under symptomatic control with a topical corticosteroid, and the patient is being monitored for manifestation in other organs and systems.
Conclusion: Lesions of DISR may occur isolated in the oral mucosa. Therefore, this complication must be considered in the differential diagnosis of oral granulomatous lesions in patients under treatment with anti-TNF-α drugs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jormas.2023.101543 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Soluble IL-2 receptor levels support diagnosis of sarcoidosis-like reaction in melanoma patients on immunotherapy - a diagnostic algorithm based on a single center retrospective study.
J Dtsch Dermatol Ges
August 2025
Department of Dermatology, Venereology and Allergology, University Medical Center Leipzig, Leipzig, Germany.
Background And Objectives: Drug-induced sarcoidosis-like reaction (DISR) is an adverse event with emerging importance during immune checkpoint inhibitor (ICI) treatment in melanoma patients. Its reported frequency varies widely, making accurate diagnosis crucial. Distinguishing DISR from tumor progression is challenging, and misdiagnosis may lead to detrimental treatment changes.
View Article and Find Full Text PDFCase Report: Hepatic sarcoidosis-like reaction from neoadjuvant pembrolizumab in early-stage triple-negative breast cancer.
Front Immunol
July 2025
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Drug-induced sarcoidosis-like reaction (DISR) is a rare adverse event associated with immunotherapy. Currently, there is no standardized treatment protocol for DISR linked to immune checkpoint inhibitors (ICIs). This study presents a case of an early-stage triple-negative breast cancer (TNBC) patient who developed hepatic sarcoidosis-like reactions during neoadjuvant pembrolizumab therapy.
View Article and Find Full Text PDF[Drug-induced sarcoidosis-like reaction due to dasatinib in the lung of a patient with chronic myeloid leukemia].
Rinsho Ketsueki
June 2025
Department of Hematology, Toyama Prefectural Central Hospital.
The patient was a 54-year-old woman with chronic myeloid leukemia. Ten months after treatment with dasatinib, she developed a cough. Imaging studies showed ground-glass patterns in the lower lung fields of both lungs, which led to suspicion of drug-induced lung injury and prompted discontinuation of dasatinib.
View Article and Find Full Text PDFA Systematic Review of Vaccine-Induced Sarcoidosis Suggests Increased Risk of Sarcoidosis Following COVID-19 mRNA Vaccine.
J Cutan Med Surg
February 2025
Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Sarcoidosis-Like Reaction in a Patient With Psoriatic Arthritis Treated With Adalimumab.
Cureus
December 2024
Internal Medicine, Hospital Infante D. Pedro, Aveiro, PRT.
A drug-induced sarcoidosis-like reaction (DISR) is a systemic granulomatous reaction indistinguishable from sarcoidosis and is associated with the administration of a medication. It typically exhibits a temporal relationship with the initiation of the drug (an average interval of 22 months) and tends to improve upon its discontinuation. Tumor necrosis factor (TNF) antagonists, including adalimumab, have been associated with the development of DISR.
View Article and Find Full Text PDF